The data of experimental and clinical analysis of a new nonsteroidal anti-inflammatory preparation amizon have been adduced. Hepatoprotective action of a drug is established on the animals with the acute toxic hepatitis in a dose of 3–5 mg/kg caused by antioxidant properties. The clinical researches have shown a high efficiency of amizon in therapy of acute and chronic diseases of a liver. The preparation promotes a cupping of the basic clinical signs of virus and toxic hepatitis, decreasing the cytolysis’ and cholestasis’ processes, lipid peroxidation. Amizon demonstrates interferonogenic properties too.
